Gastroenterology
Volume 122, Issue 5 , Pages 1216-1225, May 2002

Eosinophilic esophagitis in children: Immunopathological analysis and response to fluticasone propionate☆☆

  • Jonathan E. Teitelbaum

      Affiliations

    • Combined Program in Pediatric Gastroenterology and Nutrition
  • ,
  • Victor L. Fox

      Affiliations

    • Combined Program in Pediatric Gastroenterology and Nutrition
  • ,
  • Frank J. Twarog

      Affiliations

    • Division of Allergy and Immunology, Children's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Samuel Nurko

      Affiliations

    • Combined Program in Pediatric Gastroenterology and Nutrition
  • ,
  • Don Antonioli

      Affiliations

    • Department of Pathology
  • ,
  • Gerald Gleich

      Affiliations

    • Department of Dermatology, University of Utah, Salt Lake City, Utah
  • ,
  • Kamran Badizadegan

      Affiliations

    • Department of Pathology
  • ,
  • Glenn T. Furuta

      Affiliations

    • Combined Program in Pediatric Gastroenterology and Nutrition

Received 11 October 2001; accepted 3 January 2002.

Abstract 

Background & Aims: Eosinophilic esophagitis (EE) shares symptoms with gastroesophageal reflux disease but has distinctive pathologic features and unknown immunopathology. Treatments with antigen restriction or systemic immunosuppression pose problems with compliance and side effects. Topically applied steroids offer an attractive alternative treatment. The aims of this study were to determine the immunopathologic features of EE and the effectiveness of antigen-specific diet restriction (DR) and topical immunosuppression. Methods: A prospective trial was conducted examining the impact of DR and swallowed fluticasone propionate (FP) on pediatric patients with EE. Clinicopathologic features, including immunohistochemical analysis of the esophageal mucosa, were measured before and after treatment. Results: Immunohistochemical analysis of 11 prospectively identified children showed a significantly greater number of mucosal CD3 and CD8 lymphocytes, as well as CD1a antigen-presenting cells compared with normal controls. DR did not induce clinical improvement in any patients, whereas all children who completed treatment with FP had resolution of symptoms. Posttreatment analysis of proximal and distal esophageal mucosa showed a significant reduction in the number of eosinophils, as well as CD3+ and CD8+ lymphocytes compared with pretreatment sections. Conclusions: EE is characterized by immunologically active esophageal mucosa. FP, not DR, effectively relieves symptoms. FP significantly reduces mucosal inflammation associated with EE.

GASTROENTEROLOGY 2002;122:1216-1225

Abbreviations:  DR , diet restriction, EE , eosinophilic esophagitis, FP , fluticasone propionate, GERD , gastroesophageal reflux disease

 

 Address requests for reprints to: Glenn T. Furuta, M.D., 300 Longwood Avenue, Hunnewell Ground Floor, Boston, Massachusetts 02115. e-mail: gfuruta@zeus.bwh.harvard.edu; fax: (617) 739-5871.

☆☆ Supported by grants K08 DK 02564 and P30 DK40561 (to G.T.F.).

PII: S0016-5085(02)12378-X

Gastroenterology
Volume 122, Issue 5 , Pages 1216-1225, May 2002